LBBAP vs HBP vs BiV Pacing

Three distinct pacing strategies can achieve cardiac resynchronization in patients with left bundle branch block (LBBB) and heart failure with reduced ejection fraction. Each targets a different level of the conduction system and has unique mechanistic advantages and limitations.

Biventricular Pacing (BiV / CRT)

Biventricular pacing is the established standard for cardiac resynchronization therapy (CRT). It uses two ventricular leads — one in the RV (apex or septum) and one in a lateral or posterolateral branch of the coronary sinus (CS) — to simultaneously activate both ventricles. The mechanism of resynchronization is fusion of two wavefronts: the RV lead activates the septum and right ventricle while the LV (CS) lead pre-excites the delayed lateral LV wall. This corrects the interventricular and intraventricular dyssynchrony caused by LBBB. The classic CRT indication is LBBB with QRS ≥150 ms, LVEF ≤35%, and NYHA Class II–IV symptoms on guideline-directed medical therapy.

His Bundle Pacing (HBP)

HBP delivers pacing stimuli directly to the His bundle, the proximal conduction highway before it bifurcates into the right and left bundle branches. In patients with intra-Hisian conduction disease (the block is within the His bundle itself), high-output HBP can recruit fibers distal to the block and restore normal QRS. The mechanism is correction of the conduction delay at the His level by direct depolarization of the His fibers, which then propagate through the intact distal Purkinje system. HBP cannot correct infra-Hisian disease (block below the His in the left bundle branch itself) because the pacing stimulus does not reach the diseased tissue.

Left Bundle Branch Area Pacing (LBBAP)

LBBAP places the pacing lead deep in the interventricular septum to capture the left bundle branch or its proximal fascicles on the left septal endocardial surface. The mechanism is direct engagement of the LBB distal to the site of conduction block, pre-exciting the left ventricle via the native Purkinje network. This corrects LBBB by bypassing the block and generating rapid, physiological LV activation. LBBAP also captures local septal myocardium, producing a right ventricular activation delay (RBBB pattern in V1) that is typically hemodynamically insignificant.

The paced QRS morphology differs characteristically among the three strategies and provides immediate confirmation of the pacing modality and capture quality.

The key QRS metric for resynchronization quality is total QRS duration. HBP typically produces the narrowest QRS (equal to intrinsic when the conduction disease is correctable), followed by LBBAP (110–130 ms), then BiV (120–160 ms). However, QRS duration alone does not predict response — LV activation time (LVAT) and echocardiographic measures of dyssynchrony are more important.

BiV CRT Implant

Biventricular CRT requires three transvenous leads: a right atrial lead (RA appendage), a right ventricular lead (RV apex or septum), and a left ventricular lead placed in a tributary of the coronary sinus (CS). The LV lead is the most technically challenging component.

The CS is cannulated from the right atrium using a guiding catheter, and a venogram is performed to map the venous anatomy. The LV lead is advanced into a lateral or posterolateral CS branch — the target vessel that maximizes the distance from the RV lead to create the widest resynchronization wavefront. Key challenges include:

• CS anatomy variants: Absent or stenotic target veins, acute angulations, small-caliber branches that cannot accommodate the lead
• Diaphragmatic stimulation: The phrenic nerve runs along the lateral LV surface — CS branches in this region may cause phrenic capture, requiring repositioning
• Lead stability: CS leads are passively fixed and prone to dislodgement (~5% in the first year), particularly in tortuous or small veins
• Procedure time: CS lead placement adds 30–90 minutes to the procedure and requires significant fluoroscopy

HBP Implant

His bundle pacing uses a single ventricular lead (Medtronic 3830 SelectSecure or equivalent) delivered to the His bundle region at the apex of the triangle of Koch. The operator maps the His bundle electrogram using the pacing lead itself, then screws the fixed helix into the para-Hisian fibrous tissue. Fluoroscopic position is at the RV septum, just below the aortic annulus in RAO, and midline in LAO.

LBBAP Implant

LBBAP uses the same 3830 lead but targets the LBB on the left septal endocardium, approximately 1.5–2 cm apical to the His bundle position. The lead is advanced deep (15–25 mm) into the interventricular septum by aggressive clockwise rotation. Fluoroscopic guidance in LAO 40–45° monitors the progressive leftward advancement of the lead tip into the septum.

Key advantages of the LBBAP implant:

• Wider target: The LBB fans out across 10–15 mm of left septal endocardium — a much larger target than the compact His bundle
• Simpler than CS cannulation: No need for venography, CS anatomy navigation, or passive fixation
• No diaphragmatic stimulation risk: The lead is deep in the septum, far from the phrenic nerve
• Single-lead CRT: One lead achieves resynchronization — eliminates the CS lead and its associated complications

BiV CRT — Landmark Trials

Biventricular CRT has the strongest evidence base of any resynchronization strategy, supported by multiple large randomized controlled trials:

• COMPANION (2004): 1,520 patients with NYHA III–IV HF, LVEF ≤35%, QRS ≥120 ms. CRT-P and CRT-D both reduced the composite of death and hospitalization by 20%. CRT-D reduced all-cause mortality by 36%
• CARE-HF (2005): 813 patients with NYHA III–IV HF, LVEF ≤35%, QRS ≥120 ms (plus dyssynchrony criteria for QRS 120–149 ms). CRT-P reduced all-cause mortality by 36% over 29 months, with sustained benefit at 8-year follow-up
• MADIT-CRT (2009): Extended CRT indication to NYHA I–II patients with LBBB and QRS ≥130 ms, showing 34% reduction in HF events. Subgroup analysis confirmed benefit was driven almost entirely by LBBB patients with QRS ≥150 ms

HBP Evidence

HBP evidence is largely observational and from single-center or small multicenter studies. The His-SYNC pilot RCT (2019) randomized 41 patients to HBP vs BiV CRT and showed narrower QRS with HBP but was underpowered for clinical outcomes. HBP is supported by registry data demonstrating feasibility and physiological benefit, but no large RCT has demonstrated mortality benefit equivalent to BiV CRT. The primary limitations preventing broader adoption are threshold instability and lead performance concerns.

LBBAP Evidence

Since Huang's first description in 2017, LBBAP evidence has grown rapidly through observational studies and meta-analyses:

• LVEF improvement: Multiple studies demonstrate 8–15 percentage point LVEF improvement, comparable or superior to BiV CRT
• QRS narrowing: LBBAP consistently narrows QRS from ~160 ms to ~115–125 ms, often exceeding BiV CRT narrowing
• Super-response rate: LVEF normalization (≥50%) appears more frequent with LBBAP (30–40% in some series) compared to BiV CRT (15–25%)
• Meta-analyses (Ponnusamy 2022): Systematic review of LBBAP vs BiV CRT showed comparable LVEF improvement, with LBBAP achieving more QRS narrowing and lower implant-related complications

Non-Responders and Upgrade Strategies

Approximately 30% of BiV CRT recipients are non-responders — they do not experience meaningful LVEF improvement or symptomatic benefit. Causes include suboptimal LV lead position, large scar burden in the pacing territory, non-LBBB morphology, and AF with incomplete biventricular pacing. For these patients, upgrade to LBBAP has emerged as a promising strategy, with observational data showing significant LVEF improvement in BiV CRT non-responders who are converted to LBBAP.